Philip Kaplan, DO
Pulmonary Disease · Novi, MINPI 1295734044
Payments from drug & device makers
What this record shows
It is spread thinly across 25 manufacturers, the largest accounting for just 20.6%. Reporting peaked in 2019 at $3,481 and has fallen 62.4% since, to $1,310 in 2025.
Across 141 payments — averaging $69.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Pulmonx Corporation$1K
- Medical Device Business Services, Inc.$1K
- Pinnacle Biologics, Inc$1K
- Johnson & Johnson$1K
- GSK$840
- plus $2K from 19 others
Across 10 payments — averaging $2529.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$11K
- AstraZeneca$9K
- Gyrus ACMI, Inc.$4K
- Spiration, Inc.$2K
What the payments were for
- Travel & lodging$5,79259%
- Food & beverage$4,07241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $2,030 |
| Pulmonx Corporation | 7 | $1,422 |
| Medical Device Business Services, Inc. | 6 | $1,272 |
| Pinnacle Biologics, Inc | 9 | $1,240 |
| Johnson & Johnson | 8 | $1,146 |
| GSK | 28 | $840 |
| Philips North America LLC | 13 | $291 |
| AstraZeneca | 13 | $215 |
| Grifols USA, LLC | 7 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $190 |
| United Therapeutics Corporation | 4 | $188 |
| Boehringer Ingelheim | 7 | $175 |
| Regeneron Healthcare Solutions, Inc. | 6 | $138 |
| Sanofi | 4 | $125 |
| Electromed, Inc. | 2 | $74 |
| Intuitive Surgical | 1 | $54 |
| Baxter Healthcare | 1 | $47 |
| Verona Pharma, Inc. | 2 | $44 |
| Mylan Specialty L.p. | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Penumbra, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,864 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $53,694 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,790 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $11,473 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,961 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $1,639 |
| Azithromycin | 34 | $543 |
| Oxycodone Hcl | 17 | $382 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $156 |
| Prednisone | 29 | $78 |
| Ibuprofen | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $840 | $59,65472 claims |
| AstraZenecaBreztri Aerosphere | $215 | $13,79020 claims |
| Boehringer IngelheimStiolto Respimat | $175 | $11,47311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Novi
- Bradley RowensNovi$26K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.